Your browser doesn't support javascript.
loading
Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer.
Dai, Lei-Jie; Ma, Ding; Xu, Yu-Zheng; Li, Ming; Li, Yu-Wei; Xiao, Yi; Jin, Xi; Wu, Song-Yang; Zhao, Ya-Xin; Wang, Han; Yang, Wen-Tao; Jiang, Yi-Zhou; Shao, Zhi-Ming.
Afiliación
  • Dai LJ; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • Ma D; Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • Xu YZ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
  • Li M; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. dma09@fudan.edu.cn.
  • Li YW; Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. dma09@fudan.edu.cn.
  • Xiao Y; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. dma09@fudan.edu.cn.
  • Jin X; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • Wu SY; Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • Zhao YX; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
  • Wang H; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • Yang WT; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • Jiang YZ; Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • Shao ZM; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Nat Commun ; 14(1): 5112, 2023 08 22.
Article en En | MEDLINE | ID: mdl-37607916
The molecular heterogeneity and distinct features of HER2-low breast cancers, particularly in the Chinese population, are not well understood, limiting its precise management in the era of antibody‒drug conjugates. To address this issue, we established a cohort of 434 Chinese patients with HER2-low breast cancer (433 female and one male) and integrated genomic, transcriptomic, proteomic, and metabolomic profiling data. In this cohort, HER2-low tumors are more distinguished from HER2-0 tumors in the hormone receptor-negative subgroup. Within HER2-low tumors, significant interpatient heterogeneity also exists in the hormone receptor-negative subgroup: basal-like tumors resemble HER2-0 disease, and non-basal-like HER2-low tumors mimic HER2-positive disease. These non-basal-like HER2-low tumors are enriched in the HER2-enriched subtype and the luminal androgen receptor subtype and feature PIK3CA mutation, FGFR4/PTK6/ERBB4 overexpression and lipid metabolism activation. Among hormone receptor-positive tumors, HER2-low tumors show less loss/deletion in 17q peaks than HER2-0 tumors. In this work, we reveal the heterogeneity of HER2-low breast cancers and emphasize the need for more precise stratification regarding hormone receptor status and molecular subtype.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Límite: Female / Humans / Male Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Límite: Female / Humans / Male Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido